Eczema is a common ailment for many people, but a more severe type of eczema not as well-known, atopic dermatitis (AD), may have a new treatment option available.
AD is a more severe manifestation of eczema symptoms, and based on my previous research into the patient and caregiver community, there is a need for more awareness on their diagnosis.
A recent study from the American Association for the Advancement of Science recently released data from a phase 2 clinical trial of etokimab’s efficacy to treat AD. According to AnaptysBio, etokimab ““inhibits the activity of IL-33, a pro-inflammatory cytokine,” which can help modulate skin inflammation.
Please read more about the study here, and more about etokimab here.
Sources:
https://stm.sciencemag.org/content/11/515/eaax2945
https://www.anaptysbio.com/pipeline/etokimab/
1 Comment.
This looks like an intriguing study that warrants further research. It would be great if it can be established that this type of inhibitory activity can be connected to reduced dermatitis outbreaks.